Some big news

I thought I had posted this but just noticed it's still in my drafts.  As many know I have been on Mercks anti-pd1 drug (http://www.merck.com/about/MK-3475.html) for over a year with great results!   And you might remember me talking about a fellow warrior who desperately tried to get the drug company to allow an expanded access program.   Unfortunately for Nick, he wasn't able to get access, but it now appears others will get the opportunity. You can see some details below.  


This gives patients another drug to help fight melanoma! And hopefully means we are getting closer to it being FDA approved!

Erin
--------------------------------------------------

Expanded Access Program for MK-3475 in Advanced Melanoma

An expanded access program is now available in the U.S. for MK-3475, Merck’s investigational anti-PD-1 immunotherapy, for eligible patients with advanced melanoma who have been previously treated with ipilimumab and, if indicated, a BRAF inhibitor. The U.S. Food and Drug Administration has agreed to the initiation of this program. The study is available here(#NCT02083484).

The MK-3475 Expanded Access Program for advanced melanoma will be administered by a partner company, Idis. Physicians in the U.S. can reach Idis at 1-855-478-4347 or at mk3475us@idispharma.com. For approximately the first two months, the program will be available through physicians at MK-3475 melanoma clinical trial sites in the U.S.  Following this initial phase, the program will be open to all physicians in the U.S. who have experience using systemic treatment for melanoma.

Merck intends to expand the program to other countries in 2014. While applications outside the U.S. are not yet being accepted, Idis will be maintaining a list of physician inquiries so they can be contacted if the expanded access program becomes available in their country. Outside the U.S., physicians may contact Idis at +44 (0)1932 824 123 or mk3475row@idispharma.com.

MK-3475 is an investigational therapy and is not approved for use by any regulatory agency. An expanded access program is for patients who have serious or immediately life-threatening illnesses for which no comparable or satisfactory alternate therapies are available.




- Posted using BlogPress from my iPhone

You Might Also Like

0 comments